UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 2, 2019
COHERUS BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36721 | 27-3615821 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650)649-3530
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading | Name of each exchange on which registered | ||
Common Stock, $0.0001 par value per share | CHRS | The Nasdaq Global Market |
Item 1.01 Entry into a Material Definitive Agreement
On May 2, 2019, Coherus BioSciences, Inc. (“the Company”) and Amgen Inc. and Amgen USA Inc. (collectively, “Amgen”) entered into a confidential litigation settlement agreement and release (the “Agreement”). Under the Agreement, Amgen and Coherus have settled the trade secret action brought by Amgen against the Company that was pending in the Superior Court of California County of Ventura. The details of the settlement are confidential but the Company will continue to market UDENYCA® and will pay amid-single digit royalty to Amgen for five years.
A copy of the press release announcing the Agreement is attached as Exhibit 99.1 to this Current Report on Form8-K and is incorporated by reference into this Item 1.01.
The foregoing is only a summary of the material terms of the Agreement, does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form10-Q for the fiscal quarter ended June 30, 2019. The Company intends to redact certain portions of the Agreement pursuant to RegulationS-K, Item 601(b)(10).
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit | Description | |
99.1 | Press release dated May 2, 2019 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 3, 2019 | COHERUS BIOSCIENCES, INC. | |||||
By: | /s/ Jean-Frédéric Viret | |||||
Name: | Jean-Frédéric Viret | |||||
Title: | Chief Financial Officer |